Treatment of Seizures in People with Intellectual Disability: Treating Seizures in Intellectual Disability: L. V. Watkins et al.
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 161, doi. 10.1007/s40263-024-01149-1
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2025 AND VI 39 AND IP 2
Results: 8
1
2
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial: Evolocumab in Prevention of Early Neurological Deterioration Following Ischemic Stroke: W. Tan et al
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 197, doi. 10.1007/s40263-024-01145-5
- By:
- Publication type:
- Article
3
Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"': Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy": C. Wang et al
- Published in:
- 2025
- By:
- Publication type:
- Letter
4
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors: Impact of Cannabis Use on Mental Health: K. A. Sagar, S. A. Gruber.
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 113, doi. 10.1007/s40263-024-01148-2
- By:
- Publication type:
- Article
5
Correction: Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta‑Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder: Cariprazine, a Network Meta-analysis Across the Psychosis Spectrum: L. Tarchi et al
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
6
Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis: Ecopipam in Patients with Tourette Syndrome: P. K. Panda et al.
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 127, doi. 10.1007/s40263-024-01140-w
- By:
- Publication type:
- Article
7
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease: Evaluation of Deutetrabenazine Dosages (> 48 mg/d versus ≤ 48 mg/d) for Chorea in Huntington Disease: S. Frank et al
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 185, doi. 10.1007/s40263-024-01139-3
- By:
- Publication type:
- Article
8
Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease: Emerging Drugs for Psychosis and Agitation in Alzheimer's Disease: C. Imbimbo et al.
- Published in:
- CNS Drugs, 2025, v. 39, n. 2, p. 143, doi. 10.1007/s40263-024-01133-9
- By:
- Publication type:
- Article